|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PGA5 |
Gene summary for PGA5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PGA5 | Gene ID | 5222 |
| Gene name | pepsinogen A5 | |
| Gene Alias | Pg5 | |
| Cytomap | 11q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | P0DJD9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5222 | PGA5 | Pat01-B | Human | Stomach | GC | 5.55e-06 | -4.78e-01 | 0.5754 |
| 5222 | PGA5 | Pat02-B | Human | Stomach | GC | 2.02e-08 | -4.78e-01 | 0.0368 |
| 5222 | PGA5 | Pat03-B | Human | Stomach | GC | 1.15e-04 | -4.78e-01 | 0.3693 |
| 5222 | PGA5 | Pat06-B | Human | Stomach | GC | 1.22e-04 | -4.78e-01 | -0.1961 |
| 5222 | PGA5 | Pat12-B | Human | Stomach | GC | 2.08e-03 | -4.66e-01 | 0.0325 |
| 5222 | PGA5 | Pat15-B | Human | Stomach | GC | 1.69e-07 | -1.42e-01 | -0.0778 |
| 5222 | PGA5 | Pat16-B | Human | Stomach | GC | 2.02e-08 | -4.78e-01 | 0.1918 |
| 5222 | PGA5 | Pat17-B | Human | Stomach | GC | 8.56e-06 | -4.69e-01 | 0.3109 |
| 5222 | PGA5 | Pat18-B | Human | Stomach | GC | 2.79e-04 | -4.78e-01 | -0.0432 |
| 5222 | PGA5 | Pat19-B | Human | Stomach | GC | 1.58e-02 | -4.78e-01 | 0.0826 |
| 5222 | PGA5 | Pat24-B | Human | Stomach | GC | 3.33e-09 | -1.58e-02 | -0.1184 |
| 5222 | PGA5 | Pat25-A | Human | Stomach | CAG with IM | 2.02e-08 | -4.74e-01 | -0.1648 |
| 5222 | PGA5 | Pat26-A | Human | Stomach | CSG | 2.02e-08 | -4.78e-01 | -0.2402 |
| 5222 | PGA5 | Pat28-A | Human | Stomach | CSG | 2.19e-48 | 6.34e-01 | -0.2594 |
| 5222 | PGA5 | Pat29-A | Human | Stomach | CAG with IM | 9.13e-32 | 6.66e-01 | -0.2769 |
| 5222 | PGA5 | NAG_1 | Human | Stomach | CSG | 1.47e-03 | -4.78e-01 | -0.3534 |
| 5222 | PGA5 | NAG_2 | Human | Stomach | CSG | 6.13e-03 | -4.78e-01 | -0.3324 |
| 5222 | PGA5 | CAG_2 | Human | Stomach | CAG | 2.02e-08 | -4.78e-01 | -0.2831 |
| 5222 | PGA5 | CAG_3 | Human | Stomach | CAG | 1.03e-04 | -4.78e-01 | -0.2766 |
| 5222 | PGA5 | WIM_1 | Human | Stomach | WIM | 6.13e-03 | -4.78e-01 | 0.0335 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0007586 | Stomach | GC | digestion | 38/1159 | 137/18723 | 1.80e-15 | 1.22e-12 | 38 |
| GO:00075861 | Stomach | CAG with IM | digestion | 29/1050 | 137/18723 | 4.42e-10 | 6.93e-08 | 29 |
| GO:00075862 | Stomach | CSG | digestion | 25/1034 | 137/18723 | 1.15e-07 | 8.25e-06 | 25 |
| GO:00075863 | Stomach | CAG | digestion | 17/552 | 137/18723 | 6.00e-07 | 4.32e-05 | 17 |
| GO:00075864 | Stomach | WIM | digestion | 17/426 | 137/18723 | 1.48e-08 | 1.95e-06 | 17 |
| GO:00075865 | Stomach | SIM | digestion | 24/708 | 137/18723 | 3.20e-10 | 6.29e-08 | 24 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PGA5 | SNV | Missense_Mutation | c.839C>G | p.Thr280Ser | p.T280S | P0DJD9 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| PGA5 | SNV | Missense_Mutation | c.1003N>A | p.Ala335Thr | p.A335T | P0DJD9 | protein_coding | deleterious(0.02) | probably_damaging(0.942) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PGA5 | SNV | Missense_Mutation | c.929N>C | p.Ser310Thr | p.S310T | P0DJD9 | protein_coding | tolerated(0.06) | benign(0.166) | TCGA-E9-A1RF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| PGA5 | SNV | Missense_Mutation | rs200405121 | c.787N>A | p.Gly263Arg | p.G263R | P0DJD9 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AA-3994-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
| PGA5 | SNV | Missense_Mutation | rs757055059 | c.745N>A | p.Glu249Lys | p.E249K | P0DJD9 | protein_coding | tolerated(0.09) | possibly_damaging(0.646) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PGA5 | SNV | Missense_Mutation | c.989N>T | p.Pro330Leu | p.P330L | P0DJD9 | protein_coding | deleterious(0.01) | probably_damaging(0.982) | TCGA-AG-3592-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PGA5 | SNV | Missense_Mutation | novel | c.1001N>A | p.Ser334Asn | p.S334N | P0DJD9 | protein_coding | deleterious(0.03) | possibly_damaging(0.713) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PGA5 | SNV | Missense_Mutation | rs752639813 | c.1066N>A | p.Glu356Lys | p.E356K | P0DJD9 | protein_coding | tolerated(0.59) | benign(0.07) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PGA5 | SNV | Missense_Mutation | novel | c.949N>A | p.Leu317Met | p.L317M | P0DJD9 | protein_coding | tolerated(1) | benign(0.075) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PGA5 | deletion | Frame_Shift_Del | novel | c.819delN | p.Ala274ProfsTer10 | p.A274Pfs*10 | P0DJD9 | protein_coding | TCGA-B5-A0JN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5222 | PGA5 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 252166834 | ||
| 5222 | PGA5 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | CHEMBL2367706 | SUCRALFATE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |